Showing 971-980 of 1046 results for "".
- Roche Files for FDA Emergency Use Authorization for SARS-CoV-2 Rapid Antigen Testhttps://modernod.com/news/roche-files-for-fda-emergency-use-authorization-for-sars-cov-2-rapid-antigen-test/2478844/Roche announced it has submitted for FDA Emergency Use Authorization (EUA) for a SARS-CoV-2 Rapid Antigen Test that is designed for use by health care professionals in point-of-care settings with patients experiencing symptoms of COVID-19. The test is designed to help health care professi
- Zenni Releases New Anti-Fog Glasses Lenses to Address Mask-Related Fogginghttps://modernod.com/news/zenni-releases-new-anti-fog-glasses-lenses-to-address-mask-related-fogging/2478797/Zenni announced a 2-in-1 anti-fog + anti-reflective lens solution to solve a pain point for glasses wearers during the pandemic. Developed in 2020 as a response to the pervasive consumer issue of glasses fogging up while wearing face coverings, these new anti-fog coated lenses are the only low pr
- CheckedUp Launches Virtual Visits Telehealth Platform for Specialty Carehttps://modernod.com/news/checkedup-launches-virtual-visits-telehealth-platform-for-specialty-care/2477689/CheckedUp announced the launch of CheckedUp Virtual Visits, a telemedicine system designed to improve virtual specialty care. CheckedUp Virtual Visits was created to keep patients and physicians at the center of pivotal health care decisions as “point of care” engagement evolves with pa
- Ortho, Eurofins Lay Out Plans for High-Throughput COVID-19 Antibody Blood Testinghttps://modernod.com/news/ortho-eurofins-lay-out-plans-for-high-throughput-covid-19-antibody-blood-testing/2477541/While most antibody blood tests, including the one officially authorized by the FDA last week, have so far focused on providing rapid results at the point-of-care—by using a small test strip and a fingerprick, like a blood sugar test—others are working to deploy high-throughput versions
- FDA Authorizes Hand-Held COVID-19 Diagnostic Testhttps://modernod.com/news/fda-authorizes-hand-held-covid-19-diagnostic-test/2477452/In response to the coronavirus crisis, we’ve seen COVID-19 diagnostics quickly evolve from early, multistep kits to high-throughput versions to fast point-of-care tests, all in just a few weeks. Now, the FDA has granted an emergency authorization to a device that fits in the palm of you
- HumanOptics Receives CE Mark for Trifocal Lens Triva-aAhttps://modernod.com/news/humanoptics-receives-ce-mark-for-trifocal-lens-triva-aa/2477310/HumanOptics AG has received CE marking and approval in the European market for its new trifocal lens Triva-aA. Triva-aA is the first multifocal lens from HumanOptics with three focal points. Its optimized design enables patients to enjoy good vision not only at long and near distances, but
- Retina Specialist Brett Foxman, MD, Earns U.S. Patent for Scleral Depressorhttps://modernod.com/news/retina-specialist-brett-foxman-md-earns-u-s-patent-for-scleral-depressor/2476788/Brett Foxman, MD, Clinical Service Chief in Ophthalmology at Shore Medical Center in Somers Point, New Jersey, recently won a U.S. patent for his new version of the scleral depressor. Dr. Foxman said after performing thousands of eye surgeries using a tool that had stayed essentially uncha
- Perspective: Protocol V Sheds Light on Managing Mild Diabetic Macular Edemahttps://modernod.com/news/perspective-protocol-v-sheds-light-on-managing-mild-diabetic-macular-edema/2479555/When it comes to the treatment of diabetic macular edema (DME), ophthalmologists have overwhelming evidence to guide their decision-making—but only up to a point. DME consists of three clinical subcategories: center-involved DME (CI-DME) with visual acuity (VA) impairment, CI-DME with good
- EKF Quo-Test Supports Improved Medical Management of Diabetic Retinopathy Patientshttps://modernod.com/news/ekf-quo-test-supports-improved-medical-management-of-diabetic-retinopathy-patients/2476736/EKF Diagnostics announced that its Quo-Test HbA1c analyzer is supporting improved medical management of patients with sight-threatening diabetic retinopathy (DR). The effectiveness of this point-of-care HbA1c testing application for rapid assessment of glycaemic control in eye clinic patients has
- Ocular Therapeutix OTX-TP Intracanalicular Insert Fails to Meet Phase 3 Endpointhttps://modernod.com/news/ocular-therapeutix-otx-tp-intracanalicular-insert-fails-to-meet-phase-3-endpoint/2476598/Ocular Therapeutix’s intracanalicular insert failed to meet its primary endpoint of statistically significant superiority in mean reduction of IOP compared with placebo at all nine time points, according to a company news release. OTX-TP is an intracanalicular insert that delivers a